Advertisement

Interferone pp 202-214 | Cite as

Interferon in der Behandlung des multiplen Myeloms

  • H. Ludwig

Zusammenfassung

Seit der Einführung von Melphalan und Cyclophosphamid in die Behandlung des multiplen Myeloms konnten wesentliche Verbesserungen der zytostatischen und supportiven Therapie erreicht werden. Trotzdem sind die mit diesen konventionellen Behandlungsmaßnahmen erreichbaren mittleren Überlebenszeiten von 20–32 Monaten nach wie vor unbefriedigend [1], Dies mag mit ein Grund gewesen sein, warum die ersten Fallberichte über eine erfolgreiche Behandlung von Myelompatienten mit Interferon besonderen Optimismus auslöste. 1979 berichteten Ideström und Ma. [2] über einen gegenüber Melphalanresistenten Patienten, der unter Behandlung mit 3–6 x 106 U Leukozyteninterferon eine deutliche Reduktion seines Tumors erreichte. In einem weiteren, im selben Jahr veröffentlichten Bericht [3] wurden 4 bereits chemotherapieresistente Patienten beschrieben, die alle auf eine Interferonbehandlung angesprochen hatten, wobei 2 dieser Patienten sogar eine komplette Remission erreichten. In einer nachfolgenden größer angelegten Studie erzielte dieselbe Arbeitsgruppe jedoch mit einer Gesamtansprechrate von 14% weit weniger eindrucksvolle Resultate.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Ludwig H (1982) Multiples Myelom. Diagnose, Klinik und Therapie. Berlin-Heidelberg-New York: SpringerGoogle Scholar
  2. 2.
    Ideström K, Cantell K, Killander D, Nilsson K, Strander H, Willems J (1979) Interferon therapy in multiple myeloma. Acta Med Scand 205: 149–154PubMedCrossRefGoogle Scholar
  3. 3.
    Mellstedt H, Ahre A, Björkholm M, Holm G, Johansson B, Strander H (1979) Interferon therapy in myelomatosis. Lancet i: 245–248Google Scholar
  4. 4.
    Guttermann JU, Blumenschein GR, Alexanian R, Hweeyoung Y, Buzdar AU, Cabanillas F, Hortobagyi GN, et al. (1980) Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med 93: 399–406Google Scholar
  5. 5.
    Alexanian R, Guttermann J, Levy H (1982) Interferon treatment for multiple myeloma. In Salmon, SE (ed.): Clinics in Haematology. London-Philadelphia-Toronto: Saunders, pp 211–220Google Scholar
  6. 6.
    Ludwig H, Swetly P (1980) In vitro inhibitory effect of interferon on multiple myeloma stem cells. Cancer Immunol Immunther 9: 139–143Google Scholar
  7. 7.
    Brenning G, Ahre A, Nilsson K (1985) Correlation between in vitro and in vivo sensitivity to human leukocyte interferon in patients with multiple myeloma. Scand J Haematol 5: 543–549Google Scholar
  8. 8.
    Brenning G (1985) The in vitro effect of leukocyte alpha-interferon on human myeloma cells in a semisolid agar culture system. Scand J Haematol 35: 178–185PubMedCrossRefGoogle Scholar
  9. 9.
    Quesada JR, Alexanian R, Hawkins M, Barlogie B, Borden E, Itri L, Guttermann JU (1986) Treatment of multiple myeloma with recombinant alpha-interferon. Blood 67: 275–278PubMedGoogle Scholar
  10. 10.
    Welander CE (1987) Overview of preclinical and clinical studies of interferon alpha-2b in combination with cytotoxic drugs. Invest N Drugs Suppl 5: 47–59Google Scholar
  11. 11.
    Aapro MS, Alberts DS, Salmon SE (1983) Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay. Cancer Chemother Pharmacol 10: 161–166PubMedCrossRefGoogle Scholar
  12. 12.
    Ahre A, Björkholm M, Mellstedt H, Brenning G, Engstedt L, Gahrton G, Gyllenhammar H, et al (1984) Human leukocyte interferon and intermittent high dose melphalan/ prednisone administration in the treatment of multiple myeloma. A randomized clinical trial. Cancer Treat Rep 68: 1331–1338Google Scholar
  13. 13.
    Quesada JR, Hawkins M, Horning S, Alexanian R, Borden E, Merigan T, Adams F, et al. (1984) Collaborative phase I-II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma and multiple myeloma. Am J Med 77: 427–432PubMedCrossRefGoogle Scholar
  14. 14.
    Costanzi JJ, Cooper R, Scarffe JH, Ozer H, Grubbs SS, Ferresi RW, Pollard R, et al. (1985) Phase II study of recombinant alpha-2 interferon in resistant multiple myeloma. J Clin Oncol 3: 645–659Google Scholar
  15. 15.
    Wagstaff J, Loynds P, Scarffe JH (1985) Phase II study of rDNA human alpha-2 inter¬feron in multiple myeloma. Cancer Treat Rep 69: 495–498PubMedGoogle Scholar
  16. 16.
    Takaku F (1985) Phase II study of interferon alpha-2 (Sch 30500) for hematopoietic tumors. Rinsyo Iyaku, 1: 59–68Google Scholar
  17. 17.
    Ludwig H, Cortelezzi A, Scheithauer W, Van Camp BGK, Kuzmits R, Fillet G, Peetermans M, et al. (1986) Recombinant interferon alpha-2C versus polychemotherapy ( VMCP) for treatment of multiple myeloma: A prospective randomized trial. Eur J Cancer Clin Oncol 22: 1111–1116Google Scholar
  18. 18.
    Ohno R, Kimura K (1986) Treatment of multiple myeloma with recombinant interferon alpha-2a. Cancer 57: 1685–1688PubMedCrossRefGoogle Scholar
  19. 19.
    Kimura K (1984) A cooperative phase I-II study of HLBI in patients with malignant tumors. Jap J Cancer Chemother 11: 1324–1331Google Scholar
  20. 20.
    Rodrigez MA, Prinz WA, Sibbit WC, Bankhurst AD, Williams RC (1983) Alpha-interferon increases immunoglobulin production in cultured human mononuclear leukocytes. J Immunol 130: 1215–1219Google Scholar
  21. 21.
    Cooper MR, Fefer A, Thompson J, Case DC, Kempf R, Sacher R, Neefe J, et al (1986) Alpha-2 interferon/melphalan/prednisone in previously untreated patients with multiple myeloma: A phase I-II trial. Cancer Treat Rep 70: 473–476Google Scholar
  22. 22.
    Case DC, Fefer A, Thompson J, Cooper MR, Bonnern EM (1985) Alpha-2 interferon (Intron A) and adriamycin in the treatment of relapsing/refractory multiple myeloma. New Orleans: Proc Am Soc Hematol p. 213Google Scholar
  23. 23.
    Ludwig H, Cortelezzi A, Fritz E, Kührer I, Polli E, Scheithauer W, Flener R (1987) Combined interferon-polychemotherapy versus polychemotherapy in multiple myeloma: A phase-Ill study. In: Cantell K, Schellekens H (eds): The Biology of the Interferon System. Dordrecht-Boston-Lancaster: Martinus Nijhoff Publishers, pp. 363–370CrossRefGoogle Scholar
  24. 24.
    Österborg A, Björkholm M, Gahrton G, Grimfors G, Gyllenhammar H, Hast R, Holm G, et al. (1987) Melphalan/prednisone (MP) therapy vs melphalan/prednisone + human alpha-interferon (MP/IFN) therapy in patients with multiple myeloma, stage II and III. A randomized study from the Myeloma Group of Central Sweden (MGCS). An interimistic report. Stockholm: Proc Ann Meet Swed Med Soc, p. 169Google Scholar
  25. 25.
    Oken MM, Kyle RA, Greipp PR, Kay NE, O’Connel T, O’Connel MJ (1988) Alternating cycles of VMCP with interferon (rIFN-alpha2) in the treatment of multiple myeloma. Proc ASCO 7: 225Google Scholar
  26. 26.
    Mandelli F, Tribalto M, Cantonetti M, Petrucci MT, Boccadoro M, Pijeri A, Marmount F, et al. (1987) Recombinant alpha 2b interferon as maintenance therapy in responding multiple myeloma patients M84 protocol. Report of the Italian Multiple Myeloma Study Group. (Preliminary results). 4th Eur Conf clin Oncol (ECCO), Madrid, Nov. 1–4Google Scholar
  27. 27.
    Ohno R (1987) Interferons in the treatment of multiple myeloma. Int J Cancer Suppl 1: 14–20PubMedCrossRefGoogle Scholar
  28. 28.
    Furue H (1985) Phase II clinical study on interferon-alfa, produced from human lymphoblast (Interferon-alfa), for malignant tumor. Rinsho Iyaku 1: 1103–1121Google Scholar
  29. 29.
    Tsubura E (1986) The phase I and early phase II studies of human lymphoblast interferon (MOR-22) in the treatment of malignant tumors. J Jap Soc Cancer Ther 21: 1049–1058Google Scholar
  30. 30.
    Billiau A, Bioemmen J, Bogaerts M, Claeys H, Van Damme J, De Ley M, De Somer P, et al. (1981) Interferon therapy in multiple myeloma: Failure of human fibroblast interferon administration to alter the course of light chain disease. Eur J Cancer 17: 875–882Google Scholar
  31. 31.
    Ezaki K, Ogawa M, Okabe K, Abe K, Inove K, Horikoshi N, Inagaki J (1982) Clinical and immunological studies of human fibroblast interferon. Cancer Chemother Pharmacol 8: 47–55PubMedCrossRefGoogle Scholar
  32. 32.
    Misset JL, Mathe G, Gastiaburn H, Goutner A, Dorval T, Gouveia J, Hayat J, et al (1982) Treatment of lymphoid neoplasia by interferon. I. Human fibroblastic interferon (beta) in malignant gammapathies phase II trial. Anticancer Res 2: 63–66Google Scholar
  33. 33.
    Fossa SD (1987) Improved subjective tolerability of interferon by combination with prednisolone. Eur J Cancer Clin Oncol 23: 875–876PubMedCrossRefGoogle Scholar
  34. 34.
    Selby PJ, McElwain TJ, Nandi AC, Perren TJ, Powles RL, Tillyer CR, Osborne JR, et al (1987) Multiple myeloma treated with high dose intravenous melphalan. Brit J Haematol 66: 55–62Google Scholar
  35. 35.
    Croghan M, Durie B, Vela E, Dalton W, Tu F (1987) Paradoxic increased sensitivity of chemotherapy resistant myeloma cells to the biologic agents TNF-alpha, TNF-beta, IFN-alpha 2B plus corticosteroids. Proc Am Meet Am Ass Cancer Res 28: 404Google Scholar
  36. 36.
    Brenning G, Jernberg H, Gidlund M, Sjoeberg O, Nilsson K (1986) The effect of alpha and gamma-interferon on proliferation and production of IgE and beta 2-microglobulin in the human myeloma cell line U-266 and in an alpha-interferon resistant U-266 subline. Scand J Haematol 37: 280–288PubMedGoogle Scholar
  37. 37.
    Kurschel E, Metz-Kurschel U, Hofmann W, Niederle N (1987) Untersuchungen zur Erfassung der Nephrotoxizität von humanem alpha-2b-Interferon unter Berücksichtigung der Analyse von Harnenzymen bei Patienten mit chronischer myeloischer Leukämie. Klin Wschr 65: 667–672PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • H. Ludwig

There are no affiliations available

Personalised recommendations